198 related articles for article (PubMed ID: 27044537)
1. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration.
Kawakami I; Kobayashi Z; Arai T; Yokota O; Nonaka T; Aoki N; Niizato K; Oshima K; Higashi S; Katsuse O; Hosokawa M; Hasegawa M; Akiyama H
Acta Neuropathol Commun; 2016 Apr; 4():36. PubMed ID: 27044537
[TBL] [Abstract][Full Text] [Related]
2. An autopsy case of frontotemporal lobar degeneration with the appearance of fused in sarcoma inclusions (basophilic inclusion body disease) clinically presenting corticobasal syndrome.
Matsumoto A; Suzuki H; Fukatsu R; Shimizu H; Suzuki Y; Hisanaga K
Neuropathology; 2016 Feb; 36(1):77-87. PubMed ID: 26227957
[TBL] [Abstract][Full Text] [Related]
3. FUS pathology in basophilic inclusion body disease.
Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
[TBL] [Abstract][Full Text] [Related]
4. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
[TBL] [Abstract][Full Text] [Related]
5. Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.
Kobayashi Z; Kawakami I; Arai T; Yokota O; Tsuchiya K; Kondo H; Shimomura Y; Haga C; Aoki N; Hasegawa M; Hosokawa M; Oshima K; Niizato K; Ishizu H; Terada S; Onaya M; Ikeda M; Oyanagi K; Nakano I; Murayama S; Akiyama H; Mizusawa H
J Neurol Sci; 2013 Dec; 335(1-2):89-95. PubMed ID: 24050818
[TBL] [Abstract][Full Text] [Related]
6. Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.
A Armstrong R
Folia Neuropathol; 2017; 55(3):185-192. PubMed ID: 28984110
[TBL] [Abstract][Full Text] [Related]
7. Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
Davidson YS; Robinson AC; Hu Q; Mishra M; Baborie A; Jaros E; Perry RH; Cairns NJ; Richardson A; Gerhard A; Neary D; Snowden JS; Bigio EH; Mann DM
Neuropathol Appl Neurobiol; 2013 Feb; 39(2):157-65. PubMed ID: 22497712
[TBL] [Abstract][Full Text] [Related]
8. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
[TBL] [Abstract][Full Text] [Related]
10. Unusual clinical presentation and neuropathology in two subjects with fused-in sarcoma (FUS) positive inclusions.
Hartikainen PH; Pikkarainen M; Hänninen T; Soininen H; Alafuzoff I
Neuropathology; 2012 Feb; 32(1):60-8. PubMed ID: 21518013
[TBL] [Abstract][Full Text] [Related]
11. Distinct pathological subtypes of FTLD-FUS.
Mackenzie IR; Munoz DG; Kusaka H; Yokota O; Ishihara K; Roeber S; Kretzschmar HA; Cairns NJ; Neumann M
Acta Neuropathol; 2011 Feb; 121(2):207-18. PubMed ID: 21052700
[TBL] [Abstract][Full Text] [Related]
12. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.
Urwin H; Josephs KA; Rohrer JD; Mackenzie IR; Neumann M; Authier A; Seelaar H; Van Swieten JC; Brown JM; Johannsen P; Nielsen JE; Holm IE; ; Dickson DW; Rademakers R; Graff-Radford NR; Parisi JE; Petersen RC; Hatanpaa KJ; White CL; Weiner MF; Geser F; Van Deerlin VM; Trojanowski JQ; Miller BL; Seeley WW; van der Zee J; Kumar-Singh S; Engelborghs S; De Deyn PP; Van Broeckhoven C; Bigio EH; Deng HX; Halliday GM; Kril JJ; Munoz DG; Mann DM; Pickering-Brown SM; Doodeman V; Adamson G; Ghazi-Noori S; Fisher EM; Holton JL; Revesz T; Rossor MN; Collinge J; Mead S; Isaacs AM
Acta Neuropathol; 2010 Jul; 120(1):33-41. PubMed ID: 20490813
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic variability within the inclusion body spectrum of basophilic inclusion body disease and neuronal intermediate filament inclusion disease in frontotemporal lobar degenerations with FUS-positive inclusions.
Gelpi E; Lladó A; Clarimón J; Rey MJ; Rivera RM; Ezquerra M; Antonell A; Navarro-Otano J; Ribalta T; Piñol-Ripoll G; Pérez A; Valldeoriola F; Ferrer I
J Neuropathol Exp Neurol; 2012 Sep; 71(9):795-805. PubMed ID: 22892522
[TBL] [Abstract][Full Text] [Related]
14. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
[TBL] [Abstract][Full Text] [Related]
15. Frontotemporal lobar degeneration: diversity of FTLD lesions.
Seilhean D; Bielle F; Plu I; Duyckaerts C
Rev Neurol (Paris); 2013 Oct; 169(10):786-92. PubMed ID: 24035575
[TBL] [Abstract][Full Text] [Related]
16. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS.
Gittings LM; Foti SC; Benson BC; Gami-Patel P; Isaacs AM; Lashley T
Acta Neuropathol Commun; 2019 Feb; 7(1):18. PubMed ID: 30755280
[TBL] [Abstract][Full Text] [Related]
18. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
[TBL] [Abstract][Full Text] [Related]
19. Expanding the Phenotype of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FUS).
Chornenka K; Hirsch-Reinshagen V; Perez-Rosendahl M; Feldman H; Segal-Gidan F; Vinters HV; Mackenzie IR
J Neuropathol Exp Neurol; 2020 Jul; 79(7):809-812. PubMed ID: 32483606
[TBL] [Abstract][Full Text] [Related]
20. Increase in wasteosomes (corpora amylacea) in frontotemporal lobar degeneration with specific detection of tau, TDP-43 and FUS pathology.
Alsina R; Riba M; Pérez-Millan A; Borrego-Écija S; Aldecoa I; Romera C; Balasa M; Antonell A; Lladó A; Compta Y; Del Valle J; Sánchez-Valle R; Pelegrí C; Molina-Porcel L; Vilaplana J
Acta Neuropathol Commun; 2024 Jun; 12(1):97. PubMed ID: 38879502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
